TABLE 2.
Baseline Characteristics of Post-Outreach Enrollees, by Cumulative Statin Exposure at Baseline (2005)
| Total N = 6,975 n (%) | Baseline Cumulative Statin Exposure Categories | |||||
|---|---|---|---|---|---|---|
| None n = 1,231 % | 1-120 n = 2,252 % | 121-240 n = 1,785 % | 241-360 n = 1,487 % | > 360 n = 220 % | ||
| Age, mean [SD] | 64.5 [12.0] | 57.0 [12.6] | 64.6 [12.1] | 66.5 [10.9] | 67.8 [10.1] | 67.1 [10.2] |
| Age, category | ||||||
| < 50 years | 661 (9.5) | 28.4 | 8.5 | 4.4 | 2.6 | 1.8 |
| 50 to < 60 years | 2,180 (31.3) | 42.5 | 32.9 | 28.9 | 22.7 | 29.6 |
| 60 to < 70 years | 1,870 (26.8) | 12.2 | 25.9 | 30.8 | 35.2 | 29.1 |
| 70 to < 80 years | 1,357 (19.5) | 8.4 | 19.1 | 21.1 | 26.0 | 27.3 |
| 80+ years | 907 (13.0) | 8.5 | 13.6 | 14.9 | 13.6 | 12.3 |
| Male | 3,322 (47.6) | 47.2 | 45.1 | 49.6 | 50.0 | 43.6 |
| Hypertension | 2,570 (36.9) | 24.1 | 39.1 | 38.3 | 41.6 | 41.4 |
| Coronary artery disease | 392 (5.6) | 1.8 | 5.0 | 5.8 | 8.6 | 11.8 |
| Congestive heart failure | 81 (1.2) | 0.7 | 1.4 | 1.3 | 1.1 | 0.9 |
| Chronic pulmonary disease | 2,506 (35.9) | 35.8 | 37.6 | 35.0 | 34.8 | 35.0 |
| Stroke | 243 (3.5) | 1.0 | 3.5 | 4.5 | 4.1 | 5.0 |
| Myocardial infarction | 198 (2.8) | 0.7 | 2.1 | 3.7 | 4.3 | 5.5 |
| Atrial fibrillation | 594 (8.5) | 4.6 | 8.4 | 8.9 | 11.0 | 12.3 |
| Charlson score, mean [SD] | 1.41 [0.96] | 1.13 [0.84] | 1.48 [0.97] | 1.43 [0.99] | 1.50 [0.96] | 1.56 [1.02] |
| Diabetes complications | ||||||
| Nephropathy | 708 (10.2) | 7.6 | 10.2 | 10.4 | 11.5 | 13.2 |
| Neuropathy | 746 (10.7) | 7.5 | 10.5 | 11.2 | 12.9 | 12.3 |
| Peripheral vascular disease | 192 (2.8) | 1.8 | 3.2 | 2.6 | 3.1 | 2.7 |
| Retinopathy | 404 (5.8) | 4.4 | 5.6 | 5.5 | 7.0 | 10.5 |
| Diabetes treatment intensity | ||||||
| Diet alone | 2,308 (33.1) | 42.2 | 40.0 | 28.5 | 21.7 | 21.4 |
| Oral hypoglycemics | 3,107 (44.5) | 39.9 | 38.4 | 47.3 | 49.8 | 45.9 |
| Insulin | 1,560 (22.4) | 18.0 | 20.6 | 24.2 | 28.6 | 32.7 |
| Duration of diabetes | ||||||
| < 1 year | 677 (9.7) | 17.4 | 16.4 | 3.4 | 1.8 | 2.7 |
| 1 to < 2 years | 519 (7.4) | 8.4 | 7.9 | 11.2 | 2.1 | 4.1 |
| 2 to < 3 years | 497 (7.1) | 6.4 | 6.3 | 7.7 | 7.7 | 11.4 |
| 3 to < 5 years | 952 (13.7) | 15.0 | 13.4 | 13.6 | 13.0 | 14.1 |
| 5 to < 10 years | 1,994 (28.6) | 28.2 | 26.9 | 27.6 | 32.9 | 27.7 |
| 10+ years | 2,336 (33.5) | 24.7 | 29.2 | 36.6 | 42.6 | 40.0 |
| ACEI/ARB use | ||||||
| Cumulative at baseline | ||||||
| 700 or less | 2,775 (39.8) | 64.0 | 51.8 | 30.0 | 16.8 | 15.9 |
| 701 to 1,400 | 978 (14.0) | 9.7 | 11.9 | 18.3 | 15.5 | 15.0 |
| 1,401 to 2,100 | 661 (9.5) | 6.9 | 7.7 | 10.3 | 13.1 | 11.4 |
| > 2,100 | 2,561 (36.7) | 19.4 | 28.6 | 41.4 | 54.6 | 57.7 |
ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; SD = standard deviation.